Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXSNASDAQ:CELCNASDAQ:CGCNASDAQ:QIPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.35+5.9%$2.34$1.90▼$6.08$194.68M2.52715,096 shs775,962 shsCELCCelcuity$11.81+0.3%$11.04$7.58▼$19.77$447.20M0.37288,396 shs121,249 shsCGCCanopy Growth$1.29-2.3%$1.42$0.77▼$8.65$237.19M0.756.11 million shs8.94 million shsQIPTQuipt Home Medical$1.80-2.7%$1.95$1.35▼$4.07$78.20M0.56380,155 shs570,422 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+5.86%-0.42%-3.29%-7.84%-13.92%CELCCelcuity+0.25%-5.44%+10.48%+12.80%-20.69%CGCCanopy Growth-2.27%-17.83%-21.34%+14.16%-81.81%QIPTQuipt Home Medical-2.70%-15.09%+29.03%-22.08%-45.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXSCodexis3.7534 of 5 stars3.33.00.02.52.31.70.6CELCCelcuity1.7722 of 5 stars3.60.00.00.02.52.50.0CGCCanopy Growth2.2173 of 5 stars2.52.00.00.01.90.01.3QIPTQuipt Home Medical2.393 of 5 stars3.52.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.50Moderate Buy$11.00368.09% UpsideCELCCelcuity 3.17Buy$30.80160.80% UpsideCGCCanopy Growth 1.00Sell$2.0055.04% UpsideQIPTQuipt Home Medical 3.00Buy$2.8558.33% UpsideCurrent Analyst Ratings BreakdownLatest CDXS, CELC, QIPT, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025CGCCanopy GrowthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight5/19/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/14/2025QIPTQuipt Home MedicalBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $4.005/13/2025QIPTQuipt Home MedicalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$4.00 ➝ $1.704/11/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/1/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/1/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$59.35M3.28N/AN/A$0.82 per share2.87CELCCelcuityN/AN/AN/AN/A$3.11 per shareN/ACGCCanopy Growth$225.65M1.05N/AN/A$1.90 per share0.68QIPTQuipt Home Medical$240.85M0.32$1.02 per share1.77$2.49 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$65.28M-$0.99N/AN/AN/A-149.47%-118.47%-53.37%8/6/2025 (Estimated)CELCCelcuity-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)CGCCanopy Growth-$429.86M-$4.04N/AN/AN/A-195.76%-88.54%-40.78%8/8/2025 (Estimated)QIPTQuipt Home Medical-$6.76M-$0.21N/AN/AN/A-3.66%-8.38%-3.63%8/13/2025 (Estimated)Latest CDXS, CELC, QIPT, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q4 2025CGCCanopy Growth-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million5/14/2025Q1 2025CDXSCodexis-$0.20-$0.25-$0.05-$0.25$10.38 million$7.54 million5/14/2025Q1 2025CELCCelcuity-$0.95-$0.86+$0.09-$0.86N/AN/A5/12/2025Q2 2025QIPTQuipt Home Medical$0.02-$0.07-$0.09-$0.07$88.29 million$57.40 million3/31/2025Q4 2024CELCCelcuity-$0.72-$0.85-$0.13-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/ACELCCelcuityN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/AQIPTQuipt Home MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.593.723.64CELCCelcuity1.146.616.61CGCCanopy Growth0.623.122.10QIPTQuipt Home Medical0.761.220.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%CELCCelcuity63.33%CGCCanopy Growth3.33%QIPTQuipt Home Medical42.85%Insider OwnershipCompanyInsider OwnershipCDXSCodexis2.10%CELCCelcuity15.77%CGCCanopy Growth1.30%QIPTQuipt Home Medical13.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25082.85 million81.11 millionOptionableCELCCelcuity4037.87 million31.90 millionOptionableCGCCanopy Growth3,150183.87 million181.48 millionOptionableQIPTQuipt Home Medical1,20043.44 million37.62 millionOptionableCDXS, CELC, QIPT, and CGC HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 17 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 16 at 1:46 PM | accessnewswire.comQuipt Home Medical Corp. (NASDAQ:QIPT) Sees Significant Increase in Short InterestJune 15, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 13, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 11, 2025 | accessnewswire.comInvestigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Quipt Home Medical Corp. (QIPT)June 10, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 10, 2025 | globenewswire.comKanen Wealth Management LLC Raises Stock Holdings in Quipt Home Medical Corp. (NASDAQ:QIPT)June 10, 2025 | marketbeat.comStock Traders Purchase Large Volume of Quipt Home Medical Call Options (NASDAQ:QIPT)June 10, 2025 | americanbankingnews.comLevi & Korsinsky Investigates Quipt Home Medical Corp. (QIPT) Over Potential Securities Fraud AllegationsJune 9, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 9, 2025 | accessnewswire.comInvestigation Opened on Behalf of Quipt Home Medical Corp. (QIPT) Shareholders - Contact Levi & KorsinskyJune 9, 2025 | accessnewswire.comQuipt Home Medical Target of Unusually High Options Trading (NASDAQ:QIPT)June 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Quipt Home Medical Corp. - QIPTJune 6, 2025 | globenewswire.comGreater Cincinnati public company receives hostile buyout offer, stock skyrocketsMay 25, 2025 | local12.comQuipt Home Medical (QIPT) Gets a Buy from Stifel NicolausMay 24, 2025 | theglobeandmail.comQuipt Home Medical (NASDAQ:QIPT) Rating Lowered to Sell at Wall Street ZenMay 24, 2025 | marketbeat.comQuipt Home Medical Corp.: Quipt Home Medical Confirms Receipt of Unsolicited Acquisition ProposalMay 21, 2025 | finanznachrichten.deQuipt Home Medical Receives Acquisition Proposal from ForagerMay 21, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, CELC, QIPT, and CGC Company DescriptionsCodexis NASDAQ:CDXS$2.35 +0.13 (+5.86%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.36 +0.01 (+0.60%) As of 06/18/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Celcuity NASDAQ:CELC$11.81 +0.03 (+0.25%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$12.54 +0.73 (+6.18%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Canopy Growth NASDAQ:CGC$1.29 -0.03 (-2.27%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+1.16%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Quipt Home Medical NASDAQ:QIPT$1.80 -0.05 (-2.70%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.81 +0.01 (+0.56%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
